Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>On our latest WTR Healthcare Happenings podcast, we welcomed back Mitch Steiner, CEO of Veru, Inc. (NASDAQ: VERU) to fill us in on the company’s latest significant developments and progress made since his previous appearance on our podcast in February 2025.</li><li>Having divested its sexual health business for $18 million last year, Veru has pivoted toward the burgeoning obesity market with its lead drug candidate enobosarm, which selectively causes fat loss, while preserving lean mass in patients taking GLP-1 for weight loss.</li><li>The state of the GLP-1 market for obesity. Steiner offered his take on the latest trends in the rapidly evolving GLP-1 market for weight loss.</li></ul>

On our latest WTR Healthcare Happenings podcast, we welcomed back Mitch Steiner, CEO of Veru, Inc. (NASDAQ: VERU) to fill us in on the company’s latest significant developments and progress made since his previous appearance on our podcast in February 2025.Having divested its sexual health business for $18 million last year, Veru has pivoted toward the burgeoning obesity market with its lead drug candidate enobosarm, which selectively causes fat loss, while preserving lean mass in patients taking GLP-1 for weight loss.The state of the GLP-1 market for obesity. Steiner offered his take on the latest trends in the rapidly evolving GLP-1 market for weight loss.

Why Veru’s Enobosarm Can Fan the Flames of the Hot GLP-1 Weight Loss Market